BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Möckel T, Basta F, Weinmann-Menke J, Schwarting A. B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev 2021;20:102736. [PMID: 33333233 DOI: 10.1016/j.autrev.2020.102736] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
Number Citing Articles
1 Lin M, Boonsopon S, Manhapra A, Zhao T, Foster CS. Elevated serum BAFF in patients with ocular cicatricial pemphigoid. Canadian Journal of Ophthalmology 2022. [DOI: 10.1016/j.jcjo.2022.11.011] [Reference Citation Analysis]
2 Hanai S, Kobayashi Y, Ito R, Harama K, Nakagomi D. Thrombotic microangiopathy with refractory lupus nephritis successfully treated by combining rituximab with belimumab. Scandinavian Journal of Rheumatology 2022. [DOI: 10.1080/03009742.2022.2140483] [Reference Citation Analysis]
3 Xiao F, Rui K, Shi X, Wu H, Cai X, Lui KO, Lu Q, Ballestar E, Tian J, Zou H, Lu L. Epigenetic regulation of B cells and its role in autoimmune pathogenesis. Cell Mol Immunol 2022;19:1215-34. [PMID: 36220996 DOI: 10.1038/s41423-022-00933-7] [Reference Citation Analysis]
4 Liu J, Guan F. B cell phenotype, activity, and function in idiopathic nephrotic syndrome. Pediatr Res 2022. [DOI: 10.1038/s41390-022-02336-w] [Reference Citation Analysis]
5 Wang Y, Huang Z, Xiao Y, Wan W, Yang X. The shared biomarkers and pathways of systemic lupus erythematosus and metabolic syndrome analyzed by bioinformatics combining machine learning algorithm and single-cell sequencing analysis. Front Immunol 2022;13:1015882. [DOI: 10.3389/fimmu.2022.1015882] [Reference Citation Analysis]
6 Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T, Zeb S, Tariq MA, Patlolla SR, Ali J, Hashim SN, Hashim S. An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management. Cureus 2022. [DOI: 10.7759/cureus.30330] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Beckley MA, Shrestha S, Singh KK, Portman MA. The role of mitochondria in the pathogenesis of Kawasaki disease. Front Immunol 2022;13:1017401. [DOI: 10.3389/fimmu.2022.1017401] [Reference Citation Analysis]
8 Wang H, Li C, Ren G, Yang C, Sun J, Zhao L, Sun W, Ju J, Xu D. Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus. Autoimmunity Reviews 2022. [DOI: 10.1016/j.autrev.2022.103213] [Reference Citation Analysis]
9 Liu S, Miao JJ, Zhou X, Sun Q, Mao XM. High levels of thyroid hormones promote recurrence of Graves' disease via overexpression of B-cell-activating factor. J Clin Lab Anal 2022;:e24701. [PMID: 36097969 DOI: 10.1002/jcla.24701] [Reference Citation Analysis]
10 Kirou KA, Dall`era M, Aranow C, Anders H. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol 2022;13:980079. [DOI: 10.3389/fimmu.2022.980079] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Samões B, Zen M, Abelha-Aleixo J, Gatto M, Doria A. Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus. Autoimmun Rev 2022;21:103165. [PMID: 35931316 DOI: 10.1016/j.autrev.2022.103165] [Reference Citation Analysis]
12 Grange L, Chalayer E, Boutboul D, Paul S, Galicier L, Gramont B, Killian M. TAFRO syndrome: A severe manifestation of Sjogren's syndrome? A systematic review. Autoimmun Rev 2022;21:103137. [PMID: 35803499 DOI: 10.1016/j.autrev.2022.103137] [Reference Citation Analysis]
13 Cheng H, Zhang X, Yang H, Yu Z, Yan C, Gao C, Wen H. Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus. Front Immunol 2022;13:911730. [DOI: 10.3389/fimmu.2022.911730] [Reference Citation Analysis]
14 Alturaiki W. Considerations for Novel COVID-19 Mucosal Vaccine Development. Vaccines (Basel) 2022;10:1173. [PMID: 35893822 DOI: 10.3390/vaccines10081173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
15 Wang W, Fan Y, Wang X. Lactobacillus: Friend or Foe for Systemic Lupus Erythematosus? Front Immunol 2022;13:883747. [PMID: 35677055 DOI: 10.3389/fimmu.2022.883747] [Reference Citation Analysis]
16 Mubariki R, Vadasz Z. The role of B cell metabolism in autoimmune diseases. Autoimmun Rev 2022;:103116. [PMID: 35595053 DOI: 10.1016/j.autrev.2022.103116] [Reference Citation Analysis]
17 Liang SJ, Zheng QY, Li MS, Lv MY, Chen WT, Yang Y. Response to belimumab in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a case-based review. Clin Rheumatol 2022. [PMID: 35524885 DOI: 10.1007/s10067-022-06155-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhang F, Xu Z, He X, Sun Y, Zhao C, Zhang J, Jiang WH. Increased B Cell-Activating Factor Expression Is Associated with Postoperative Recurrence of Chronic Rhinosinusitis with Nasal Polyps. Mediators of Inflammation 2022;2022:1-11. [DOI: 10.1155/2022/7338692] [Reference Citation Analysis]
19 Mak A, Chan JKY. Endothelial function and endothelial progenitor cells in systemic lupus erythematosus. Nat Rev Rheumatol 2022. [PMID: 35393604 DOI: 10.1038/s41584-022-00770-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Doyon-Laliberté K, Aranguren M, Poudrier J, Roger M. Marginal Zone B-Cell Populations and Their Regulatory Potential in the Context of HIV and Other Chronic Inflammatory Conditions. Int J Mol Sci 2022;23:3372. [PMID: 35328792 DOI: 10.3390/ijms23063372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Takeda A, Hasegawa E, Yawata N, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, Kimura K, Sonoda KH. Increased vitreous levels of B cell activation factor (BAFF) and soluble interleukin-6 receptor in patients with macular edema due to uveitis related to Behçet's disease and sarcoidosis. Graefes Arch Clin Exp Ophthalmol 2022. [PMID: 35230474 DOI: 10.1007/s00417-022-05600-1] [Reference Citation Analysis]
22 Lim YL, Bohelay G, Hanakawa S, Musette P, Janela B. Autoimmune Pemphigus: Latest Advances and Emerging Therapies. Front Mol Biosci 2022;8:808536. [DOI: 10.3389/fmolb.2021.808536] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
23 Tanaka Y; The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. Belimumab: A BAFF-specific Inhibitor for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis. Rheumatology 2022;1:32. [DOI: 10.17925/rmd.2022.1.1.32] [Reference Citation Analysis]
24 van Beers JJ, Schreurs MW. Anti-Sm antibodies in the classification criteria of systemic lupus erythematosus. Journal of Translational Autoimmunity 2022;5:100155. [DOI: 10.1016/j.jtauto.2022.100155] [Reference Citation Analysis]
25 Zhang Y, Tian J, Xiao F, Zheng L, Zhu X, Wu L, Zhao C, Wang S, Rui K, Zou H, Lu L. B cell-activating factor and its targeted therapy in autoimmune diseases. Cytokine & Growth Factor Reviews 2021. [DOI: 10.1016/j.cytogfr.2021.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Raymond WD, Hamdorf M, Furfaro M, Eilertsen GO, Nossent JC. Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus. Lupus Sci Med 2021;8:e000537. [PMID: 34725185 DOI: 10.1136/lupus-2021-000537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhou B, Li S, Ye J, Liu Y, Hu L, Tang Y, Wu Z, Zhang P. Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19. Int Immunopharmacol 2021;101:108254. [PMID: 34710657 DOI: 10.1016/j.intimp.2021.108254] [Reference Citation Analysis]
28 Wang Y, Xiao S, Xia Y, Wang H. The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies. Clin Rev Allergy Immunol 2021. [PMID: 34542806 DOI: 10.1007/s12016-021-08898-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Naučno-praktičeskaâ revmatologiâ 2021;59:367-383. [DOI: 10.47360/1995-4484-2021-367-383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Quartuccio L, De Marchi G, Longhino S, Manfrè V, Rizzo MT, Gandolfo S, Tommasini A, De Vita S, Fox R. Shared Pathogenetic Features Between Common Variable Immunodeficiency and Sjögren's Syndrome: Clues for a Personalized Medicine. Front Immunol 2021;12:703780. [PMID: 34322134 DOI: 10.3389/fimmu.2021.703780] [Reference Citation Analysis]
31 Fagone P, Mangano K, Di Marco R, Reyes-Castillo Z, Muñoz-Valle JF, Nicoletti F. Altered Expression of TSPAN32 during B Cell Activation and Systemic Lupus Erythematosus. Genes (Basel) 2021;12:931. [PMID: 34207245 DOI: 10.3390/genes12060931] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Basta F, Möckel T, Petersohn J, Meineck M, Triantafyllias K, Engel S, Weinmann A, Luessi F, Weinmann-Menke J, Schwarting A. The relationship between BAFF serum levels, anti-NMDAR autoantibodies and fatigue in patients with systemic lupus erythematosus and multiple sclerosis. Autoimmun Rev 2021;20:102802. [PMID: 33727153 DOI: 10.1016/j.autrev.2021.102802] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]